title: In-vitro cyclosporin sensitivity of proliferating lymphocytes is predictive of in-vivo therapeutic response in ulcerative colitis.
abstract: BACKGROUND
  The efficacy of cyclosporin in the management of ulcerative colitis is recognized. Not all patients respond to this treatment. Existing clinical and laboratory parameters are of little use in identifying those most likely to respond.
  
  
  OBJECTIVE
  To determine whether in-vitro sensitivity to cyclosporin as measured by a lymphocyte proliferation assay is predictive of in-vivo response to therapy.
  
  
  METHODS
  The study comprised seven responders with ulcerative colitis, seven non-responders, and 14 healthy matched controls. A lymphocyte proliferation assay was carried out in the presence of a range of concentrations of cyclosporin and a dose-response curve constructed for each subject. The IC(50) value, the concentration of cyclosporin that resulted in 50% inhibition of proliferation, was calculated for each subject. IC(50) values for responders, non-responders and controls were compared using a Mann-Whitney test.
  
  
  RESULTS
  There was a wide range of values obtained for the study group as a whole. IC(50) values for non-responders were significantly higher than those of responders (P < 0.05).
  
  
  CONCLUSIONS
  There is a population-wide variation of in-vitro sensitivity to cyclosporin. This is reflected in in-vivo sensitivity as measured by clinical response to cyclosporin treatment. Future therapeutic strategies need to address this inherent variability of individual response to therapy.
authors.affiliation: Department of Gastroenterology and Liver Unit, St Vincent's University Hospital, Dublin, Ireland.
authors.forename: G
authors.initials: G
authors.lastname: McCormack
authors.forename: D
authors.initials: D
authors.lastname: O'Donoghue
authors.forename: A
authors.initials: A
authors.lastname: Baird
mesh_terms: D000328:Adult; D018929:Cell Culture Techniques; D002455:Cell Division / Q000187:drug effects; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D016572:Cyclosporine / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008214:Lymphocytes / Q000187:drug effects* / Q000502:physiology; D011237:Predictive Value of Tests; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine